CTS1 gene therapy
Latest Information Update: 04 Jul 2002
At a glance
- Originator Aventis
- Class Antineoplastics; Gene therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 21 Jul 2000 New profile
- 21 Jul 2000 Preclinical development for Cancer in France (Unknown route)